Analyst firms · Oppenheimer · EDIT

Oppenheimer EDIT price target and rating history

Editas Medicine Inc. (EDIT) · Health Care

Oppenheimer rates Editas Medicine Inc. (EDIT) Perform with a $12 price target, as of its latest action on Nov 18, 2022. It has published 3 rating actions on EDIT since September 2021, including 1 upgrade and 1 downgrade. Across 3 firms with a EDIT price target in the last 12 months, the median target is $6.

Current rating
Perform
Price target
$12
Median target, all firms
$6
Actions on EDIT
3

Oppenheimer price target on EDIT

$40$26$1220222023202420252026
Oppenheimer price target on EDIT, each point a stated target, September 2021 to November 2022. Targets before November 2022 (divided by 2) are adjusted for a stock split, going by the prior target Oppenheimer restated.

Every Oppenheimer rating on EDIT

How other firms rate EDIT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Wells FargoOverweight$6Oct 8, 2026
GuggenheimBuy$5Sep 23, 2026
Ladenburg ThalmannBuy$6Aug 18, 2026

Questions about Oppenheimer and EDIT

What is Oppenheimer's price target for EDIT?
Oppenheimer's latest stated price target for Editas Medicine Inc. (EDIT) is $12, from its action on Nov 18, 2022.
What is Oppenheimer's rating on EDIT?
Oppenheimer rates EDIT Perform, a neutral rating, as of Nov 18, 2022.
When did Oppenheimer last change its view on EDIT?
On Nov 18, 2022, Oppenheimer downgrades to Perform from Outperform, price target $28 to $12.
How does Oppenheimer's EDIT target compare with other analysts?
Across 3 firms with a EDIT price target in the last 12 months, the median target is $6.

More EDIT rating histories

All Oppenheimer ratingsEDIT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.